Happy New Year. I trust you had a relaxing time over the holidays with family and friends as well as a great start into 2019. Golden Helix certainly had a landmark year. There were many highlights that actually shaped the direction for us in the years to come. Please let me mention a few:
- We launched VSClinical in May 2018: This product is supporting the clinical variant interpretation based on ACMG & AMP guidelines. The product was an instant hit.
- We received a $1.8M research grant from the NIH that allows us to continue to refine our CNV analysis capabilities, deeply integrate CNV analytics capability with clinical workflows and explore ways of how to detect other structural variants.
- CIO Applications chose us to be among the top 10 Biotechnology Solution Providers in 2018.
Read the full story on Our 2 SNPs… here.